Abstract:Rabies, caused by the rabies virus (RABV), is the most fatal zoonotic disease. It is a neglected tropical disease which remains a major public health problem, causing approximately 59,000 deaths worldwide annually. Despite the existence of effective vaccines, the high incidence of human rabies is mainly linked to tedious vaccine immunisation procedures and the overall high cost of post-exposure prophylaxis. Therefore, it is necessary to develop an effective vaccine that has a simple procedure and is affordable to prevent rabies infection in humans. RABV belongs to the genus Lyssavirus and family Rhabdoviridae. Previous phylogenetic analyses have identified seven major clades of RABV in China (China I-VII), confirmed by analysing nucleotide sequences from both the G and N proteins. This study evaluated the immunogenicity and protective capacity of SYS6008, an mRNA rabies vaccine expressing rabies virus glycoprotein, in mice and cynomolgus macaques. We demonstrated that SYS6008 induced sufficient levels of rabies neutralising antibody (RVNA) in mice. In addition, SYS6008 elicited strong and durable RVNA responses in vaccinated cynomolgus macaques. In the pre-exposure prophylaxis murine model, one or two injections of SYS6008 at 1/10 or 1/30 of dosage provided protection against a challenge with a 30-fold LD<sub>50</sub> of rabies virus (China I and II clades). We also demonstrated that in the post-exposure prophylaxis murine model, which was exposed to lethal rabies virus (China I-VII clades) before vaccination, one or two injections of SYS6008 at both 1/10 and 1/30 dosages provided better protection against rabies virus challenge than the immunization by five injections of commercial vaccines at the same dosage. In addition, we proved that SYS6008-induced RVNAs could neutralise RABV from the China I-VII clades. Finally, 1/10 of the dosage of SYS6008 was able to stimulate significant RABV-G specificity in the T cell response. Furthermore, we found that SYS6008 induced high cellular immunity, including RABV-G-specific T cell responses and memory B cells. Our results imply that the SYS6008 rabies vaccine, with a much simpler vaccination procedure, better immunogenicity, and enhanced protective capacity, could be a candidate vaccine for post-exposure prophylaxis of rabies infections.

A Novel Rabies Vaccine Based on a Recombinant Parainfluenza Virus 5 Expressing Rabies Virus Glycoprotein.

Cell Surface Display of Rabies Virus Glycoprotein by Using Ice Nucleation Protein

Parainfluenza virus 5 expressing the G protein of rabies virus protects mice after rabies virus infection.

A Novel Rabies Vaccine Based on a Recombinant Bovine Herpes Virus Type 1 Expressing Rabies Virus Glycoprotein

A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge

A novel mRNA rabies vaccine as a promising candidate for rabies post-exposure prophylaxis protects animals from different rabies viruses

Recombinant Adeno-Associated Virus Serotype 9 AAV-RABVG Expressing a Rabies Virus G Protein Confers Long-Lasting Immune Responses in Mice and Non-Human Primates

A single dose of an ALVAC vector-based RABV virus-like particle candidate vaccine induces a potent immune response in mice, cats and dogs

A Novel Rabies Vaccine Based on the Chimpanzee Adenoviral Vector AdC68

AAV-expressed G protein induces robust humoral and cellular immune response and provides durable protection from rabies virus challenges in mice

Recombinant Rabies Virus with the Glycoprotein Fused with a DC-binding Peptide is an Efficacious Rabies Vaccine.

A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice

A Recombinant Canine Distemper Virus Expressing a Modified Rabies Virus Glycoprotein Induces Immune Responses in Mice

A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes.

Construction of Recombinant Rabies Virus Vectors Expressing H or F Protein of Peste des Petits Ruminants Virus

An mRNA vaccine against rabies provides strong and durable protection in mice

Rabies-based vaccine induces potent immune responses against Nipah virus

A recombinant rabies virus encoding two copies of the glycoprotein gene confers protection in dogs against a virulent challenge.

A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity

A Novel Oral Rabies Vaccine Enhances the Immunogenicity Through Increasing Dendritic Cells Activation and Germinal Center Formation by Expressing U-OMP19 in a Mouse Model

Construction and Evaluation of Recombinant Lactobacillus Plantarum NC8 Delivering One Single or Two Copies of G Protein Fused with a DC-targeting Peptide (dcpep) As Novel Oral Rabies Vaccine.